BRPI0416461A - method for treating bleeding episodes, pharmaceutical formulation, and use of a fxi polypeptide - Google Patents

method for treating bleeding episodes, pharmaceutical formulation, and use of a fxi polypeptide

Info

Publication number
BRPI0416461A
BRPI0416461A BRPI0416461-0A BRPI0416461A BRPI0416461A BR PI0416461 A BRPI0416461 A BR PI0416461A BR PI0416461 A BRPI0416461 A BR PI0416461A BR PI0416461 A BRPI0416461 A BR PI0416461A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
bleeding episodes
polypeptide
treating bleeding
methods
Prior art date
Application number
BRPI0416461-0A
Other languages
Portuguese (pt)
Inventor
Rasmus Rojkjaer
Dorthe Viuff
Soren Ostergaard
Simon Bjerregaard Jensen
Jens Jacob Hansen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0416461A publication Critical patent/BRPI0416461A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21027—Coagulation factor XIa (3.4.21.27)

Abstract

"MéTODO PARA O TRATAMENTO DE EPISóDIOS DE SANGRAMENTO, FORMULAçãO FARMACêUTICA, E, USO DE UM POLIPEPTìDEO FXI". A presente invenção fornece métodos e composições para o tratamento de episódios de sangramento. Os métodos são realizados pela administração a um paciente em necessidade deste, uma preparação que compreende um polipeptídeo de fator XI, em uma quantidade eficaz para tal tratamento. Os métodos da invenção resultam em um ou mais de: tempo de coagulação reduzido; intensificação da hemostase; aumento no tempo de lise do coágulo; aumento na concentração de coágulo; e/ou aumento na qualidade total do coágulo (OCQ) no dito paciente."METHOD FOR TREATING BLOOD EPISODES, PHARMACEUTICAL FORMULATION, AND USE OF AN FXI POLYPEPTIDE". The present invention provides methods and compositions for treating bleeding episodes. The methods are performed by administering to a patient in need thereof a preparation comprising a factor XI polypeptide in an amount effective for such treatment. The methods of the invention result in one or more of: reduced clotting time; intensification of hemostasis; increased clot lysis time; increase in clot concentration; and / or increase in total clot quality (OCQ) in said patient.

BRPI0416461-0A 2003-11-20 2004-11-22 method for treating bleeding episodes, pharmaceutical formulation, and use of a fxi polypeptide BRPI0416461A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301721 2003-11-20
DKPA200401141 2004-07-23
PCT/DK2004/000810 WO2005049070A1 (en) 2003-11-20 2004-11-22 Therapeutic use of factor xi

Publications (1)

Publication Number Publication Date
BRPI0416461A true BRPI0416461A (en) 2007-03-06

Family

ID=34621448

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416461-0A BRPI0416461A (en) 2003-11-20 2004-11-22 method for treating bleeding episodes, pharmaceutical formulation, and use of a fxi polypeptide

Country Status (9)

Country Link
EP (1) EP1687020A1 (en)
JP (1) JP2007513881A (en)
KR (1) KR20060118486A (en)
AU (1) AU2004290869A1 (en)
BR (1) BRPI0416461A (en)
CA (1) CA2540986A1 (en)
RU (1) RU2006115783A (en)
TW (1) TW200529870A (en)
WO (1) WO2005049070A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008266A2 (en) * 2004-07-23 2006-01-26 Novo Nordisk Health Care Ag Factor xi-binding proteins
WO2006128497A1 (en) * 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
EP2379096B1 (en) 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
EP2305289A1 (en) * 2009-09-16 2011-04-06 Bio-Products & Bio-Engineering Aktiengesellschaft Medicinal products for the treatment of blood coagulation disorders
NZ710434A (en) 2010-03-19 2017-01-27 Baxter Healthcare Sa Tfpi inhibitors and methods of use
NZ749998A (en) 2012-03-21 2023-06-30 Takeda Pharmaceuticals Co Tfpi inhibitors and methods of use
DE102012022234A1 (en) 2012-11-14 2014-05-15 Instraction Gmbh One step process for purifying (blood) plasma proteins, such as albumin from mixtures
DE102012022233A1 (en) 2012-11-14 2014-05-15 Instraction Gmbh Process for purifying a (blood) plasma protein
CR20210563A (en) 2020-04-05 2022-01-24 Pfizer Compounds and methods for the treatment of covid-19

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676231A1 (en) * 1991-05-07 1992-11-13 Aetsrn BLOOD COAGULATION FACTOR XI CONCENTRATE WITH HIGH SPECIFIC ACTIVITY, SUITABLE FOR THERAPEUTIC USE AND ITS PREPARATION PROCESS.
WO2001066747A2 (en) * 2000-03-03 2001-09-13 Curagen Corporation Proteins named fctrx and nucleic acids encoding same
IL159622A0 (en) * 2001-07-20 2004-06-01 Novo Nordisk Healthcare Ag Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides

Also Published As

Publication number Publication date
JP2007513881A (en) 2007-05-31
CA2540986A1 (en) 2005-06-02
RU2006115783A (en) 2007-12-27
KR20060118486A (en) 2006-11-23
TW200529870A (en) 2005-09-16
AU2004290869A1 (en) 2005-06-02
EP1687020A1 (en) 2006-08-09
WO2005049070A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
BR0108694A (en) Malnic acid derivatives, process for preparing them, use of them as an inhibitor of factor xa activity and pharmaceutical compositions containing the same
BRPI0510428A (en) methadone topical compositions and processes for using them
BR0214772A (en) systems and methods for treating patients with processed liposuction cells
BR0116370A (en) Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient.
ATE361084T1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING PROANTHOCYANIDINS, GLYCYRRHETINIC ACID AND TELMESTEINS FOR THE TREATMENT OF DERMATITIS
NO20045521L (en) Diarylurea derivatives useful for the treatment of protein kinase-dependent diseases
BRPI0317463B8 (en) compound, pharmaceutical composition comprising the same and use of said compound in the preparation of a medicament for treating a transthyretin amyloid disease
BR0315720A (en) Compound, method for the prophylaxis or treatment of a clinical condition in a mammal, pharmaceutical formulation, combination, use of a compound, process for the preparation of a compound, and, intermediate
BR9916732A (en) Malnic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)
BRPI0618918B8 (en) use of a first compound and a second compound to treat a blood glucose condition
BR0111381A (en) Compositions, kits and methods to promote definite health benefits
Choi et al. Inhibition of hydrogen sulfide-induced angiogenesis and inflammation in vascular endothelial cells: potential mechanisms of gastric cancer prevention by Korean red ginseng
BR0212455A (en) Compound, pharmaceutical formulation, combination, use of a compound, method for the prophylaxis or treatment of a clinical condition in a mammal, and, process for preparing a compound.
BR0209129A (en) Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds.
BR0207007A (en) Pharmaceutical composition, kit, uses of a preparation and composition, and methods for treating bleeding episodes in a patient, to reduce clotting time in a patient, to intensify hemostasis in a patient to reduce the number of administrations. of clotting factor protein needed to halt bleeding and maintain hemostasis in a patient, to reduce the amount of administered clotting factor protein needed to stop bleeding and maintain hemostasis in a patient, to prolong the lysis time of the patient. clot in a patient, to increase clot resistance in a patient and to intensify fibrin clot formation in a patient
BRPI0411982A (en) therapy improvement glycan
ECSP034883A (en) AMIDAS OF ANTRANILIC ACIDS WITH SIDE CHAIN OF HETEROARILSULFONILO, PROCEDURE FOR THEIR PREPARATION, ITS EMPLOYMENT AS A MEDICINAL OR DIAGNOSTIC AGENT, AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THEM
BRPI0416461A (en) method for treating bleeding episodes, pharmaceutical formulation, and use of a fxi polypeptide
BR9702200A (en) Bicyclic-aromatic compounds pharmaceutical composition cosmetic composition and use of a cosmetic composition
BRPI0415753A (en) method for treating and preventing respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions containing them
BR9702074A (en) Heterocyclic biaryl compounds pharmaceutical and cosmetic compositions containing them and their uses
BR0209128A (en) Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds
BR0015939A (en) Transdermal therapeutic systems with improved stability and a process for their preparation
WO2006000007A1 (en) Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock
ES549115A0 (en) PROCEDURE FOR PRODUCING PREPARATIONS TO TREAT HEMOPHILIA PATIENTS TO INHIBITORS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.